NAD Augmentation in Diabetes Kidney Disease

Phase 2

Recruiting

• Conditions: Type2diabetes; Diabetic Kidney Disease
• Interventions: Drug: Investigational Product - MIB 626; Drug: Placebo

• Registration Number: NCT05759468
• Lead Sponsor: Brigham and Women's Hospital

Brief Summary

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

Detailed Description

This will be two centers, randomized, double-blind, placebo-controlled, parallel group trial to determine whether βNMN, after its daily oral administration, is associated with a greater reduction in the UACR compared to placebo.

The trial will enroll community-dwelling older adults, 60 years or older, with type 2 diabetes mellitus (T2DM) and urine albumin to creatinine excretion ratio \> 100 mg/ g creatinine.

Study Timeline

• Study First Submitted: 2023-01-09
• Study First Submitted QC: 2023-03-06
• Study First Posted: 2023-03-08
• Status Verified: 2023-04
• Study Start: 2023-04-13
• Last Update Submitted: 2023-04-21
• Last Update Posted: 2023-04-25
• Primary Completion: 2025-12-31
• Study Completion: 2026-07-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

1. Has T2DM, as indicated by any of the following:

   1. Self-report of diabetes plus the use of a prescribed diabetes medication.
   2. ICD-10 code for diabetes plus current use of a diabetes medication in the electronic medical record.
   3. HbA1c >6.4%; or 2 fasting glucose > 125 mg/dL

2. Fasting morning UACR between 100 and 2,000 mg/g creatinine on two separate days

3. If UACR is > 300 mg/g creatinine, must be currently using an ACE inhibitor or an ARB

4. eGFR > 30 mL/ min / 1.73 m2

5. Hemoglobin A1c <9%

6. Able to speak English or Spanish

7. Willing and able to provide written informed consent

8. In addition, female participants must Not be pregnant and not planning to become pregnant over the next 6 months

Exclusion Criteria

1. Fasting morning UACR > 2,000 mg/ g creatinine

2. Other laboratory abnormalities:

   1. Has AST or ALT > 3 times the upper limit of normal
   2. creatinine > 2.5 mg/dL
   3. Hematocrit < 0.34 or 0.50 L/L

3. A major adverse cardiovascular event in preceding 3 months

4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter

5. Hypoglycemia unawareness or other medical conditions which could jeopardize participant's safety.

6. History of alcohol or substance use disorder or dependence (DSM 5 criteria) within the last 2 years.

7. Major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures.

8. BMI > 42.5 kg/ m2

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Investigational Product - MIB 626	Investigational Product - MIB 626	The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
Placebo	Placebo	Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.

Primary Outcome Measures

Name	Time	Method
The primary endpoint is the change from baseline in UACR over the 6-month intervention period.	6 months	To determine whether treatment with a microcrystalline formulation of β nicotinamide mononucleotide (βNMN) in older adults with DKD improves urinary albumin to creatinine excretion ratio (UACR), compared to placebo.

Secondary Outcome Measures

Name	Time	Method
To determine whether NMN treatment is associated with significantly greater improvement in muscle endurance.	6 month	Assess the change from baseline in muscle endurance by exercises (reps to failure) using Keiser Machines
To determine whether NMN alters the circulating biomarkers of aging that the geroscience experts have recommended.	6 months	Compared to placebo treatment, NMN treatment will be assessed to identify greater changes in the circulating biomarkers of aging. the biomarkers that will be assessed are IL6 and TNFalpha
Assess the change from baseline in the levels of NMN in the peripheral blood and in the PBMCs using a validated LC-MS/MS assay.	6 months	NMN treatment will be assessed to determine significant increases in blood levels of NAD and its metabolome during the 24-week intervention period. The increase in NAD levels are to be observed during the intervention period in NMN-treated subjects that will be sustained during the 12-week follow-up period (legacy effect).
Assess the proportion of participants in the two study arms with 30% or greater reduction in UACR	6 months	In supportive analysis of the primary outcome, the investigator will compare the proportion of participants in the two study arms with 30% or greater reduction in UACR
Assess the change from baseline over the 6-month intervention period in biomarkers of kidney injury.	6 month	Compared to placebo treatment, NMN treatment of older adults with DKD will assess for improvements in biomarkers of kidney injury in association with DKD prognosis by measuring KIM-1 and STNFR1 combinedly.
Change from baseline in the levels of serum creatinine over 6-month intervention period	6 month	To determine whether NMN treatment is associated with change in serum creatinine from baseline to 24 weeks between the two study arms.
Change from baseline in the levels of cystine C over 6-month intervention period.	6 month	To determine whether NMN treatment is associated with change in cystatin C from baseline to 24 weeks between the two study arms.
Assess the change from baseline in performance-based measures of function.	6 month	To determine whether NMN treatment is associated with significantly greater improvement in performance based by using 6-minute walking distance measure of function.
Assess the change in measure of H1bac as a measure of glycemic control over the 6 months intervention period.	6 months	To determine the effect of NMN treatment on Hb1ac (expressed in mg/dL) in the body as a measure of glycemic control.
Assess the change in measure of fasting glucose as a measure of glycemic control over the 6 months intervention period.	6 months	To determine the effect of NMN treatment on fasting glucose in the body as a measure of glycemic control.

Trial Locations

Locations (1)

Brigham and Women's Hospital; 🇺🇸 Boston, Massachusetts, United States